Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Current Leases (2020 - 2024)

Mirum Pharmaceuticals has reported Current Leases over the past 5 years, most recently at $1.7 million for Q4 2024.

  • Quarterly results put Current Leases at $1.7 million for Q4 2024, up 54.8% from a year ago — trailing twelve months through Dec 2024 was $1.7 million (up 54.8% YoY), and the annual figure for FY2024 was $1.7 million, up 54.8%.
  • Current Leases for Q4 2024 was $1.7 million at Mirum Pharmaceuticals, up from $1.5 million in the prior quarter.
  • Over the last five years, Current Leases for MIRM hit a ceiling of $1.7 million in Q4 2024 and a floor of $358000.0 in Q1 2024.
  • Median Current Leases over the past 5 years was $741500.0 (2022), compared with a mean of $850800.0.
  • Peak annual rise in Current Leases hit 54.8% in 2024, while the deepest fall reached 60.83% in 2024.
  • Mirum Pharmaceuticals' Current Leases stood at $636000.0 in 2020, then rose by 11.79% to $711000.0 in 2021, then soared by 30.94% to $931000.0 in 2022, then grew by 18.58% to $1.1 million in 2023, then skyrocketed by 54.8% to $1.7 million in 2024.
  • The last three reported values for Current Leases were $1.7 million (Q4 2024), $1.5 million (Q3 2024), and $1.1 million (Q2 2024) per Business Quant data.